Loading...
Market
How will Brenus Pharma's stock price change within one week after announcing Phase I clinical trial results?
2
Resolution / Starting Odds
Increases by more than 10% • 25%
Increases by 0-10% • 25%
Decreases by 0-10% • 25%
Decreases by more than 10% • 25%
Stock market data from financial news outlets or stock exchanges
Story
Brenus Pharma Secures €22.2M ($25M) to Accelerate Cancer Vaccine Trials
Sep 18, 2024, 07:37 AM
Brenus Pharma, a Lyon-based biotech company specializing in the development of precision cancer vaccines, has successfully raised €22.2 million ($25 million) in a Series A funding round. The financing was led by Angelor and will be used to accelerate clinical trials of its cancer vaccines. This significant investment underscores the growing interest and support for innovative cancer treatment solutions in the biotech sector.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Increase > 20% • 25%
Increase 10-20% • 25%
Increase < 10% • 25%
Decrease • 25%
Increases by more than 10% • 25%
Decreases by more than 10% • 25%
Changes by less than 10% • 25%
No significant change • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Decrease by 5-10% • 25%
Decrease by more than 10% • 25%
Stock price increases by over 20% • 25%
Stock price increases by 10-20% • 25%
Stock price changes by less than 10% • 25%
Stock price decreases • 25%
Yes • 50%
No • 50%
Stock price increases by 10% or more • 25%
Stock price decreases by 10% or more • 25%
Stock price remains within 10% of current value • 25%
Stock price fluctuates but no clear trend • 25%
Yes • 50%
No • 50%
Increase by more than 20% • 25%
Increase by 10% to 20% • 25%
Change less than 10% • 25%
Decrease • 25%